Trials / Unknown
UnknownNCT05270746
The Predictive Value of Retinal Vascular Signs for Intracranial Artery Stenosis (RVS-ICAS)
The Predictive Value of Retinal Vascular Signs for Patients With Intracranial Artery Stenosis: A Prospective, Continuity Study, Cross-sectional Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Capital Medical University · Academic / Other
- Sex
- All
- Age
- 35 Years
- Healthy volunteers
- Accepted
Summary
Intracranial artery stenosis (ICAS) is a leading cause of ischemic stroke worldwide, contributing to the global burden of stroke, particularly in the Asian population. However, there is no non-invasive, easy to popularize and economic for intracranial artery stenosis in mass population screening. This study aims to evaluate the predictive value of retinal vascular signs for intracranial artery stenosis (ICAS) and explore a new screening method.
Detailed description
Intracranial atherosclerosis stenosis (ICAS) is a leading cause of ischemic stroke worldwide, contributing to the global burden of stroke, particularly in the Asian population. Compared with the other stroke subtypes, patients with ICAS particularly the degree of stenosis≥50% had more severe stroke, stayed longer in the hospital and higher risk of recurrent ischemic events. However, there is no non-invasive, easy to popularize and economic for intracranial artery stenosis in mass population screening. Retinal imaging has great advantages including share the same embryological origin, anatomic features, and physiological properties with brain, non-invasive, easy to popularize, inexpensive and possess good economic benefits. Therefore, investigators design this study to assess the predictive value of retinal vascular signs for intracranial artery stenosis (ICAS) and hope to explore a new screening method.
Conditions
Timeline
- Start date
- 2022-02-27
- Primary completion
- 2022-06-26
- Completion
- 2022-07-01
- First posted
- 2022-03-08
- Last updated
- 2022-03-08
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05270746. Inclusion in this directory is not an endorsement.